{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:50:33Z","timestamp":1790614233872,"version":"4.1.0"},"reference-count":170,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.cellsig.2015.07.021","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T08:33:58Z","timestamp":1438245238000},"page":"224-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Arginine vasopressin receptor signaling and functional outcomes in heart failure"],"prefix":"10.1016","volume":"28","author":[{"given":"Melissa A.","family":"Wasilewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie D.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio A.","family":"Recchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur M.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas G.","family":"Tilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0005","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1161\/CIR.0b013e31828124ad","article-title":"Heart disease and stroke statistics\u20132013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"issue":"Suppl. P","key":"10.1016\/j.cellsig.2015.07.021_bb0010","first-page":"P9","article-title":"Clinical epidemiology of heart failure: public and private health burden","volume":"19","author":"McMurray","year":"1998","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0015","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","article-title":"Heart disease and stroke statistics\u20132015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.cellsig.2015.07.021_bb0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJM198402093100603","article-title":"Prostaglandins in severe congestive heart failure. Relation to activation of the renin\u2013angiotensin system and hyponatremia","volume":"310","author":"Dzau","year":"1984","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cellsig.2015.07.021_bb0025","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/0735-1097(94)90385-9","article-title":"Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the registry of studies of left ventricular dysfunction. SOLVD investigators","volume":"23","author":"Benedict","year":"1994","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.cellsig.2015.07.021_bb0030","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/0002-8703(94)90633-5","article-title":"Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia","volume":"128","author":"Leier","year":"1994","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0035","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","article-title":"The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure","volume":"20","author":"Packer","year":"1992","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9266","key":"10.1016\/j.cellsig.2015.07.021_bb0040","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cellsig.2015.07.021_bb0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0735-1097(96)00489-5","article-title":"Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the survival and ventricular enlargement (SAVE) study. SAVE investigators","volume":"29","author":"Vantrimpont","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0050","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0735-1097(98)00675-5","article-title":"Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction","volume":"33","author":"Exner","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"issue":"14","key":"10.1016\/j.cellsig.2015.07.021_bb0055","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/CIRCULATIONAHA.109.865774","volume":"120","author":"Verdecchia","year":"2009","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.cellsig.2015.07.021_bb0060","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.cellsig.2015.07.021_bb0065","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","year":"1987","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.cellsig.2015.07.021_bb0070","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.cellsig.2015.07.021_bb0075","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.cellsig.2015.07.021_bb0080","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.cellsig.2015.07.021_bb0085","doi-asserted-by":"crossref","first-page":"550","DOI":"10.7326\/0003-4819-134-7-200104030-00008","article-title":"Beta-blockers in congestive heart failure. A Bayesian meta-analysis","volume":"134","author":"Brophy","year":"2001","journal-title":"Ann. Intern. Med."},{"issue":"7","key":"10.1016\/j.cellsig.2015.07.021_bb0090","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.287.7.883","article-title":"Beta-blocker therapy in heart failure: scientific review","volume":"287","author":"Foody","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0095","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cellsig.2015.07.021_bb0100","first-page":"1045","article-title":"Guideline for the management of heart failure caused by systolic dysfunction: part II. Treatment","volume":"64","author":"Chavey","year":"2001","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.cellsig.2015.07.021_bb0105","series-title":"Cardiology Explained","article-title":"Heart Failure","author":"Ashley","year":"2004"},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-8703(02)94708-3","article-title":"Vasopressin: a new target for the treatment of heart failure","volume":"146","author":"Lee","year":"2003","journal-title":"Am. Heart J."},{"issue":"6","key":"10.1016\/j.cellsig.2015.07.021_bb0115","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","article-title":"Increased plasma arginine vasopressin levels in patients with congestive heart failure","volume":"1","author":"Goldsmith","year":"1983","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM198107303050506","article-title":"Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure","volume":"305","author":"Szatalowicz","year":"1981","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0125","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/CIRCHEARTFAILURE.112.970012","article-title":"Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial","volume":"6","author":"Lanfear","year":"2013","journal-title":"Circ. Heart Fail."},{"issue":"2","key":"10.1016\/j.cellsig.2015.07.021_bb0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10741-008-9109-7","article-title":"Hyponatremia in heart failure","volume":"14","author":"Farmakis","year":"2009","journal-title":"Heart Fail. Rev."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0140","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1527-5299.2005.04180.x","article-title":"Hyponatremia and heart failure\u2013pathophysiology and implications","volume":"11","author":"Sica","year":"2005","journal-title":"Congest. Heart Fail."},{"issue":"12A","key":"10.1016\/j.cellsig.2015.07.021_bb0145","doi-asserted-by":"crossref","first-page":"19L","DOI":"10.1016\/j.amjcard.2005.09.066","article-title":"Hyponatremia in patients with heart failure","volume":"96","author":"De Luca","year":"2005","journal-title":"Am. J. Cardiol."},{"issue":"19","key":"10.1016\/j.cellsig.2015.07.021_bb0150","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.290.19.2581","article-title":"Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model","volume":"290","author":"Lee","year":"2003","journal-title":"JAMA"},{"issue":"5847","key":"10.1016\/j.cellsig.2015.07.021_bb0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/295299a0","article-title":"Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor","volume":"295","author":"Land","year":"1982","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.cellsig.2015.07.021_bb0160","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/ki.2009.319","article-title":"Vasopressin regulation of blood pressure and volume: findings from V1a receptor-deficient mice","volume":"76","author":"Aoyagi","year":"2009","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.cellsig.2015.07.021_bb0165","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/01.RES.84.3.365","article-title":"Evidence for a vasopressin system in the rat heart","volume":"84","author":"Hupf","year":"1999","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0170","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0022-2828(03)00053-1","article-title":"The role of arginine vasopressin and its receptors in the normal and failing rat heart","volume":"35","author":"Chandrashekhar","year":"2003","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"1\u20132","key":"10.1016\/j.cellsig.2015.07.021_bb0175","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0014-2999(99)00775-X","article-title":"Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor","volume":"391","author":"Nakamura","year":"2000","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0180","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.RES.69.1.239","article-title":"Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors","volume":"69","author":"Xu","year":"1991","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0185","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/01.RES.76.4.592","article-title":"Arginine vasopressin-induced potentiation of unitary L-type Ca2+ channel current in guinea pig ventricular myocytes","volume":"76","author":"Zhang","year":"1995","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0190","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1254\/jphs.08R15FM","article-title":"New topics in vasopressin receptors and approach to novel drugs: effects of vasopressin receptor on regulations of hormone secretion and metabolisms of glucose, fat, and protein","volume":"109","author":"Tanoue","year":"2009","journal-title":"J. Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0195","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1210\/en.2006-1315","article-title":"Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice","volume":"148","author":"Aoyagi","year":"2007","journal-title":"Endocrinology"},{"issue":"1\u20133","key":"10.1016\/j.cellsig.2015.07.021_bb0200","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2007.03.022","article-title":"Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor","volume":"566","author":"Birumachi","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bbr.2006.12.009","article-title":"Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout mice","volume":"178","author":"Egashira","year":"2007","journal-title":"Behav. Brain Res."},{"issue":"7","key":"10.1016\/j.cellsig.2015.07.021_bb0210","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/MBC.0b013e328309905d","article-title":"Vasopressin acts on platelets to generate procoagulant activity","volume":"19","author":"Tomasiak","year":"2008","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0215","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1046\/j.1365-2141.1996.436975.x","article-title":"Physiologic concentrations of arginine vasopressin activate human platelets in vitro","volume":"92","author":"Wun","year":"1996","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.cellsig.2015.07.021_bb0220","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1124\/mol.65.3.623","article-title":"Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological\/knockout approach","volume":"65","author":"Oshikawa","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0225","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2826.2008.01704.x","article-title":"Pituitary-adrenal response to acute and repeated mild restraint, forced swim and change in environment stress in arginine vasopressin receptor 1b knockout mice","volume":"20","author":"Stewart","year":"2008","journal-title":"J. Neuroendocrinol."},{"issue":"14","key":"10.1016\/j.cellsig.2015.07.021_bb0230","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMra1404726","article-title":"Molecular physiology of water balance","volume":"372","author":"Knepper","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cellsig.2015.07.021_bb0235","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10157-012-0686-3","article-title":"Decreased expression of aquaporin 2 in the collecting duct of mice lacking the vasopressin V1a receptor","volume":"17","author":"Yasuoka","year":"2013","journal-title":"Clin. Exp. Nephrol."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0240","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1210\/endo.133.4.8404628","article-title":"Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats","volume":"133","author":"Ostrowski","year":"1993","journal-title":"Endocrinology"},{"issue":"1 Pt 2","key":"10.1016\/j.cellsig.2015.07.021_bb0245","first-page":"R193","article-title":"Control of renal medullary blood flow by vasopressin V1 and V2 receptors","volume":"269","author":"Nakanishi","year":"1995","journal-title":"Am. J. Physiol."},{"issue":"2","key":"10.1016\/j.cellsig.2015.07.021_bb0250","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/mol.113.086322","article-title":"Arginine vasopressin enhances cell survival via a G protein-coupled receptor kinase 2\/beta-arrestin1\/extracellular-regulated kinase 1\/2-dependent pathway in H9c2 cells","volume":"84","author":"Zhu","year":"2013","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.cellsig.2015.07.021_bb0255","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1124\/mol.59.6.1395","article-title":"Arrestin effects on internalization of vasopressin receptors","volume":"59","author":"Bowen-Pidgeon","year":"2001","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0260","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1152\/physrev.00035.2011","article-title":"Vasopressin V1a and V1b receptors: from molecules to physiological systems","volume":"92","author":"Koshimizu","year":"2012","journal-title":"Physiol. Rev."},{"issue":"12","key":"10.1016\/j.cellsig.2015.07.021_bb0265","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1074\/jbc.273.12.7155","article-title":"Transient phosphorylation of the V1a vasopressin receptor","volume":"273","author":"Innamorati","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"35","key":"10.1016\/j.cellsig.2015.07.021_bb0270","doi-asserted-by":"crossref","first-page":"27229","DOI":"10.1016\/S0021-9258(19)61501-2","article-title":"Dynamic interaction of human vasopressin\/oxytocin receptor subtypes with G protein-coupled receptor kinases and protein kinase C after agonist stimulation","volume":"275","author":"Berrada","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"1\u20134","key":"10.1016\/j.cellsig.2015.07.021_bb0275","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/10799899909036654","article-title":"Phosphorylation and recycling kinetics of G protein-coupled receptors","volume":"19","author":"Innamorati","year":"1999","journal-title":"J. Recept. Signal Transduct. Res."},{"issue":"10","key":"10.1016\/j.cellsig.2015.07.021_bb0280","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1523\/JNEUROSCI.23-10-04228.2003","article-title":"Vasopressin-induced cytoplasmic and nuclear calcium signaling in embryonic cortical astrocytes: dynamics of calcium and calcium-dependent kinase translocation","volume":"23","author":"Zhao","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cellsig.2015.07.021_bb0285","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.pharmtox.41.1.175","article-title":"The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists","volume":"41","author":"Thibonnier","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"Pt 3","key":"10.1016\/j.cellsig.2015.07.021_bb0290","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1113\/jphysiol.2001.012606","article-title":"Coupling of vasopressin-induced intracellular Ca2+ mobilization and apical exocytosis in perfused rat kidney collecting duct","volume":"538","author":"Yip","year":"2002","journal-title":"J. Physiol."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0295","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1074\/jbc.272.4.2486","article-title":"Phosphorylation of the V2 vasopressin receptor","volume":"272","author":"Innamorati","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0300","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1073\/pnas.95.5.2222","article-title":"A serine cluster prevents recycling of the V2 vasopressin receptor","volume":"95","author":"Innamorati","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"39","key":"10.1016\/j.cellsig.2015.07.021_bb0305","doi-asserted-by":"crossref","first-page":"27849","DOI":"10.1074\/jbc.M112.445098","article-title":"Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin","volume":"288","author":"Feinstein","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"45","key":"10.1016\/j.cellsig.2015.07.021_bb0310","doi-asserted-by":"crossref","first-page":"32248","DOI":"10.1074\/jbc.274.45.32248","article-title":"Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization","volume":"274","author":"Oakley","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0315","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1161\/CIRCULATIONAHA.108.765289","article-title":"Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia","volume":"118","author":"Finley","year":"2008","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0320","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/clpt.2013.240","article-title":"Vasopressin antagonists for patients with acute heart failure: interpreting new clinical and translational data","volume":"95","author":"Feldman","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"16","key":"10.1016\/j.cellsig.2015.07.021_bb0325","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.cellsig.2015.07.021_bb0330","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.cellsig.2015.07.021_bb0335","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2007.03.020","article-title":"Arginine vasopressin receptor antagonists for heart failure: a winter climbing to the Everest's tip?","volume":"49","author":"Rossi","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.cellsig.2015.07.021_bb0340","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.cellsig.2015.07.021_bb0345","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","article-title":"Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction","volume":"49","author":"Udelson","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.cellsig.2015.07.021_bb0350","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.cellsig.2015.07.021_bb0355","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrcardio.2012.181","article-title":"The disconnect between phase II and phase III trials of drugs for heart failure","volume":"10","author":"Vaduganathan","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"issue":"20","key":"10.1016\/j.cellsig.2015.07.021_bb0360","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/jama.2011.666","article-title":"Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure","volume":"305","author":"Alehagen","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.cellsig.2015.07.021_bb0365","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/eurheartj\/ehp098","article-title":"C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study","volume":"30","author":"Voors","year":"2009","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0370","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jacc.2008.03.050","article-title":"Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease","volume":"52","author":"Neuhold","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0375","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.hlc.2014.10.008","article-title":"Copeptin (C-terminal pro arginine-vasopressin) is an independent long-term prognostic marker in heart failure with reduced ejection fraction","volume":"24","author":"Pozsonyi","year":"2015","journal-title":"Heart Lung Circ."},{"issue":"6","key":"10.1016\/j.cellsig.2015.07.021_bb0380","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2217\/bmm.14.50","article-title":"Copeptin as a biomarker in heart failure","volume":"8","author":"Balling","year":"2014","journal-title":"Biomark. Med"},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0385","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0735-1097(86)80417-X","article-title":"Hemodynamic effects of infused arginine vasopressin in congestive heart failure","volume":"8","author":"Goldsmith","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.cellsig.2015.07.021_bb0390","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.cardfail.2008.06.003","article-title":"Efficacy and safety of the vasopressin V1A\/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study","volume":"14","author":"Goldsmith","year":"2008","journal-title":"J. Card. Fail."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0395","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1517\/17425255.2013.783566","article-title":"Evaluation of lixivaptan in euvolemic and hypervolemic hyponatremia and heart failure treatment","volume":"9","author":"Zmily","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0400","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCHEARTFAILURE.111.965392","article-title":"Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure","volume":"5","author":"Morooka","year":"2012","journal-title":"Circ. Heart Fail."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0405","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jacc.2013.09.032","article-title":"Increased vasopressin 1A receptor expression in failing human hearts","volume":"63","author":"Zhu","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cellsig.2015.07.021_bb0410","series-title":"Chronic Blockade of Vasopressin type1a Receptor and\/or type2 Receptor Improves Both Cardiac and Renal Damage and Dysfunction in Hypertensive Rats","volume":"vol. 34","author":"Ikeda","year":"2013"},{"issue":"20","key":"10.1016\/j.cellsig.2015.07.021_bb0415","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","article-title":"Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure","volume":"104","author":"Udelson","year":"2001","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.cellsig.2015.07.021_bb0420","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.1073\/pnas.0600875103","article-title":"V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity","volume":"103","author":"Koshimizu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0425","doi-asserted-by":"crossref","first-page":"F100","DOI":"10.1152\/ajprenal.00088.2008","article-title":"Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells","volume":"295","author":"Aoyagi","year":"2008","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0430","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cvr\/cvq034","article-title":"Decreased susceptibility to salt-induced hypertension in subtotally nephrectomized mice lacking the vasopressin V1a receptor","volume":"87","author":"Oikawa","year":"2010","journal-title":"Cardiovasc. Res."},{"issue":"Suppl. 3","key":"10.1016\/j.cellsig.2015.07.021_bb0435","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.3949\/ccjm.73.Suppl_3.S19","article-title":"The role of vasopressin in congestive heart failure","volume":"73","author":"Goldsmith","year":"2006","journal-title":"Cleve. Clin. J. Med."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0440","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1161\/CIRCULATIONAHA.111.021352","article-title":"Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through galphaq-mediated cell signaling","volume":"124","author":"Li","year":"2011","journal-title":"Circulation"},{"issue":"2\u20133","key":"10.1016\/j.cellsig.2015.07.021_bb0445","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2006.12.010","article-title":"Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice","volume":"559","author":"Hiroyama","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"20","key":"10.1016\/j.cellsig.2015.07.021_bb0450","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1161\/CIRCULATIONAHA.114.010434","article-title":"Beta-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling","volume":"130","author":"Tilley","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.cellsig.2015.07.021_bb0455","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0022-3565(24)39307-3","article-title":"Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure","volume":"293","author":"Clair","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0460","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/ki.1990.276","article-title":"Arginine vasopressin gene expression in chronic cardiac failure in rats","volume":"38","author":"Kim","year":"1990","journal-title":"Kidney Int."},{"key":"10.1016\/j.cellsig.2015.07.021_bb0465","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0079-6123(02)39023-X","article-title":"The central vasopressinergic system in experimental left ventricular hypertrophy and dysfunction","volume":"139","author":"Muders","year":"2002","journal-title":"Prog. Brain Res."},{"issue":"11","key":"10.1016\/j.cellsig.2015.07.021_bb0470","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.amjmed.2009.04.022","article-title":"Risk factors for heart failure: a population-based case\u2013control study","volume":"122","author":"Dunlay","year":"2009","journal-title":"Am. J. Med."},{"issue":"20","key":"10.1016\/j.cellsig.2015.07.021_bb0475","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","article-title":"The progression from hypertension to congestive heart failure","volume":"275","author":"Levy","year":"1996","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0480","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/01.HYP.26.5.828","article-title":"Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism","volume":"26","author":"Burrell","year":"1995","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0485","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/01.HYP.9.4.332","article-title":"Evidence against a pressor role for vasopressin in spontaneous hypertension","volume":"9","author":"Sladek","year":"1987","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0490","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2265.1994.tb02489.x","article-title":"Plasma corticotrophin releasing hormone, vasopressin, ACTH and cortisol responses to acute myocardial infarction","volume":"40","author":"Donald","year":"1994","journal-title":"Clin. Endocrinol."},{"issue":"6","key":"10.1016\/j.cellsig.2015.07.021_bb0495","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1161\/CIRCHEARTFAILURE.112.968750","article-title":"Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats","volume":"5","author":"Yamazaki","year":"2012","journal-title":"Circ. Heart Fail."},{"issue":"12","key":"10.1016\/j.cellsig.2015.07.021_bb0500","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1016\/j.peptides.2011.10.023","article-title":"The cardioprotective effect of different doses of vasopressin (AVP) against ischemia-reperfusion injuries in the anesthetized rat heart","volume":"32","author":"Nazari","year":"2011","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.cellsig.2015.07.021_bb0505","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.neulet.2011.05.049","article-title":"Down-regulation of V1a vasopressin receptors in the cerebellum after myocardial infarction","volume":"499","author":"Milik","year":"2011","journal-title":"Neurosci. Lett."},{"issue":"1\u20133","key":"10.1016\/j.cellsig.2015.07.021_bb0510","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejphar.2006.11.063","article-title":"Vasopressin V1A receptor enhances baroreflex via the central component of the reflex arc","volume":"558","author":"Oikawa","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0515","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/10253890500456287","article-title":"Enhanced involvement of brain vasopressin V1 receptors in cardiovascular responses to stress in rats with myocardial infarction","volume":"8","author":"Dobruch","year":"2005","journal-title":"Stress"},{"issue":"3","key":"10.1016\/j.cellsig.2015.07.021_bb0520","doi-asserted-by":"crossref","first-page":"R672","DOI":"10.1152\/ajpregu.00543.2009","article-title":"Brain vasopressin V(1) receptors contribute to enhanced cardiovascular responses to acute stress in chronically stressed rats and rats with myocardial infarcton","volume":"298","author":"Cudnoch-Jedrzejewska","year":"2010","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0525","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.npep.2014.07.004","article-title":"Altered expression of V1a receptors mRNA in the brain and kidney after myocardial infarction and chronic stress","volume":"48","author":"Milik","year":"2014","journal-title":"Neuropeptides"},{"issue":"2","key":"10.1016\/j.cellsig.2015.07.021_bb0530","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0014-2999(95)00503-D","article-title":"[Arg8]vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists","volume":"285","author":"Bax","year":"1995","journal-title":"Eur. J. Pharmacol."},{"issue":"5 Pt 2","key":"10.1016\/j.cellsig.2015.07.021_bb0535","first-page":"R1217","article-title":"Prolonged stimulation of intrarenal V1 vasopressin receptors results in sustained hypertension","volume":"267","author":"Szczepanska-Sadowska","year":"1994","journal-title":"Am. J. Physiol."},{"issue":"2\u20133","key":"10.1016\/j.cellsig.2015.07.021_bb0540","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-2999(01)01092-5","article-title":"Vascular and renal effects of vasopressin and its antagonists in conscious rats with chronic myocardial infarction; evidence for receptor shift","volume":"423","author":"Lankhuizen","year":"2001","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0545","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00005344-200007000-00005","article-title":"[Arg8]-vasopressin-induced responses on coronary and mesenteric arteries of rats with myocardial infarction: the effects of V1a- and V2-receptor antagonists","volume":"36","author":"Lankhuizen","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.cellsig.2015.07.021_bb0550","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/jama.2013.7832","article-title":"Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial","volume":"310","author":"Mentzelopoulos","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0555","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa0706873","article-title":"Vasopressin and epinephrine vs. epinephrine alone in cardiopulmonary resuscitation","volume":"359","author":"Gueugniaud","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.cellsig.2015.07.021_bb0560","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.resuscitation.2012.02.005","article-title":"A randomised, double-blind, multi-centre trial comparing vasopressin and adrenaline in patients with cardiac arrest presenting to or in the emergency department","volume":"83","author":"Ong","year":"2012","journal-title":"Resuscitation"},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0565","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.resuscitation.2011.07.015","article-title":"Vasopressin for cardiac arrest: meta-analysis of randomized controlled trials","volume":"83","author":"Mentzelopoulos","year":"2012","journal-title":"Resuscitation"},{"issue":"6","key":"10.1016\/j.cellsig.2015.07.021_bb0570","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ajem.2014.02.035","article-title":"Outcomes by rescue shock number during the metabolic phase of porcine ventricular fibrillation resuscitation","volume":"32","author":"Coute","year":"2014","journal-title":"Am. J. Emerg. Med."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0575","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.resuscitation.2011.09.015","article-title":"Combination pharmacotherapy improves neurological outcome after asphyxial cardiac arrest","volume":"83","author":"Varvarousi","year":"2012","journal-title":"Resuscitation"},{"issue":"2","key":"10.1016\/j.cellsig.2015.07.021_bb0580","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1460-9592.2011.03688.x","article-title":"Resuscitation strategies from bupivacaine-induced cardiac arrest","volume":"22","author":"Mauch","year":"2012","journal-title":"Paediatr. Anaesth."},{"issue":"6","key":"10.1016\/j.cellsig.2015.07.021_bb0585","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/00000539-200106000-00029","article-title":"The effects of endogenous and exogenous vasopressin during experimental cardiopulmonary resuscitation","volume":"92","author":"Krismer","year":"2001","journal-title":"Anesth. Analg."},{"issue":"12","key":"10.1016\/j.cellsig.2015.07.021_bb0590","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1097\/00003246-200012000-00001","article-title":"Comparison of epinephrine and vasopressin in a pediatric porcine model of asphyxial cardiac arrest","volume":"28","author":"Voelckel","year":"2000","journal-title":"Crit. Care Med."},{"issue":"14","key":"10.1016\/j.cellsig.2015.07.021_bb0595","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1161\/hc3901.095896","article-title":"Developing a vasopressor combination in a pig model of adult asphyxial cardiac arrest","volume":"104","author":"Mayr","year":"2001","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0600","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/00003246-200205000-00001","article-title":"Effects of epinephrine and vasopressin in a piglet model of prolonged ventricular fibrillation and cardiopulmonary resuscitation","volume":"30","author":"Voelckel","year":"2002","journal-title":"Crit. Care Med."},{"issue":"7","key":"10.1016\/j.cellsig.2015.07.021_bb0605","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s00134-010-1828-2","article-title":"Terlipressin versus adrenaline in an infant animal model of asphyxial cardiac arrest","volume":"36","author":"Lopez-Herce","year":"2010","journal-title":"Intensive Care Med."},{"issue":"3","key":"10.1016\/j.cellsig.2015.07.021_bb0610","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1186\/cc7930","article-title":"Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice","volume":"13","author":"Indrambarya","year":"2009","journal-title":"Crit. Care"},{"issue":"7","key":"10.1016\/j.cellsig.2015.07.021_bb0615","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1161\/01.CIR.99.7.925","article-title":"Adenoviral gene transfer of the human V2 vasopressin receptor improves contractile force of rat cardiomyocytes","volume":"99","author":"Laugwitz","year":"1999","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.cellsig.2015.07.021_bb0620","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1357-2725(00)00037-6","article-title":"Vasopressin-induced hypertrophy in H9c2 heart-derived myocytes","volume":"32","author":"Brostrom","year":"2000","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1\u20132","key":"10.1016\/j.cellsig.2015.07.021_bb0625","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1006961330375","article-title":"Vasopressin accelerates protein synthesis in neonatal rat cardiomyocytes","volume":"195","author":"Xu","year":"1999","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0630","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0008-6363(97)00324-6","article-title":"Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte","volume":"38","author":"Tahara","year":"1998","journal-title":"Cardiovasc. Res."},{"issue":"13","key":"10.1016\/j.cellsig.2015.07.021_bb0635","doi-asserted-by":"crossref","first-page":"9505","DOI":"10.1074\/jbc.M608874200","article-title":"Protein kinase C regulates internal initiation of translation of the GATA-4 mRNA following vasopressin-induced hypertrophy of cardiac myocytes","volume":"282","author":"Sharma","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.cellsig.2015.07.021_bb0640","doi-asserted-by":"crossref","first-page":"11255","DOI":"10.1074\/jbc.M610769200","article-title":"Arginine vasopressin-mediated cardiac differentiation: insights into the role of its receptors and nitric oxide signaling","volume":"282","author":"Gassanov","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0645","doi-asserted-by":"crossref","first-page":"H2262","DOI":"10.1152\/ajpheart.01320.2006","article-title":"Functional arginine vasopressin system in early heart maturation","volume":"293","author":"Gutkowska","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0650","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1161\/01.HYP.30.5.1112","article-title":"Arginine vasopressin increases nitric oxide synthesis in cytokine-stimulated rat cardiac myocytes","volume":"30","author":"Yamamoto","year":"1997","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0655","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/jcb.10085","article-title":"Functional receptor for platelet-derived growth factor in rat embryonic heart-derived myocytes: role of sequestered Ca2+ stores in receptor signaling and antagonism by arginine vasopressin","volume":"84","author":"Brostrom","year":"2002","journal-title":"J. Cell. Biochem."},{"issue":"6","key":"10.1016\/j.cellsig.2015.07.021_bb0660","doi-asserted-by":"crossref","first-page":"H1822","DOI":"10.1152\/ajpheart.00396.2008","article-title":"AMP-activated protein kinase influences metabolic remodeling in H9c2 cells hypertrophied by arginine vasopressin","volume":"296","author":"Saeedi","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"6","key":"10.1016\/j.cellsig.2015.07.021_bb0665","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1096\/fj.04-2201com","article-title":"Regulation of the human atrial myosin light chain 1 promoter by Ca2+\u2212calmodulin-dependent signaling pathways","volume":"19","author":"Woischwill","year":"2005","journal-title":"FASEB J."},{"issue":"6 Pt 2","key":"10.1016\/j.cellsig.2015.07.021_bb0670","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1161\/01.HYP.19.6.730","article-title":"Effects of a nonpeptide vasopressin antagonist (OPC-21268) on cytosolic Ca2+ concentration in vascular and cardiac myocytes","volume":"19","author":"Matsui","year":"1992","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0675","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000028302","article-title":"Enhancement by arginine vasopressin of the L-type Ca2+ current in guinea pig ventricular myocytes","volume":"59","author":"Kurata","year":"1999","journal-title":"Pharmacology"},{"issue":"1\u20132","key":"10.1016\/j.cellsig.2015.07.021_bb0680","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11010-008-9802-9","article-title":"Involvement of ERK and AKT signaling in the growth effect of arginine vasopressin on adult rat cardiac fibroblast and the modulation by simvastatin","volume":"317","author":"He","year":"2008","journal-title":"Mol. Cell. Biochem."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0685","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1210\/endo.136.5.7720643","article-title":"Simvastatin inhibits the cellular signaling and proliferative action of arginine vasopressin in cultured rat glomerular mesangial cells","volume":"136","author":"Ishikawa","year":"1995","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.cellsig.2015.07.021_bb0690","first-page":"333","article-title":"Arginine vasopressin stimulates proliferation of adult rat cardiac fibroblasts via protein kinase C-extracellular signal-regulated kinase 1\/2 pathway","volume":"60","author":"He","year":"2008","journal-title":"Sheng Li Xue Bao"},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0695","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/FJC.0b013e31817f36b8","article-title":"Mitogenic effect of arginine vasopressin on adult rat cardiac fibroblast: involvement of PKC-erk1\/2 pathway","volume":"52","author":"Yan-ping","year":"2008","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0700","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00005344-200307000-00020","article-title":"Effects of arginine vasopressin on growth of rat cardiac fibroblasts: role of V1 receptor","volume":"42","author":"Yang","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.cellsig.2015.07.021_bb0705","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11010-009-0155-9","article-title":"Caveolin-1 restoration by cholesterol enhances the inhibitory effect of simvastatin on arginine vasopressin-induced cardiac fibroblasts proliferation","volume":"331","author":"Liu","year":"2009","journal-title":"Mol. Cell. Biochem."},{"issue":"6","key":"10.1016\/j.cellsig.2015.07.021_bb0710","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/FJC.0000000000000151","article-title":"Effects of angiotensin-(1\u20137) on the proliferation and collagen synthesis of arginine vasopressin-stimulated rat cardiac fibroblasts: role of mas receptor-calcineurin-NF-kappaB signaling pathway","volume":"64","author":"Niu","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"11","key":"10.1016\/j.cellsig.2015.07.021_bb0715","first-page":"1044","article-title":"Inhibitory effect of cyclosporin a on growth and collagen synthesis of rat cardiac fibroblasts induced by arginine vasopressin","volume":"41","author":"Shang","year":"2006","journal-title":"Yao Xue Xue Bao"},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0720","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.lfs.2007.05.018","article-title":"Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF-kappaB activation and its relation with myocardial fibrosis","volume":"81","author":"Fan","year":"2007","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0725","first-page":"70","article-title":"[Effects of IL-1beta on inducible nitric oxide synthase-nitric oxide system activity in arginine vasopressin-induced rat cardiac fibroblasts]","volume":"23","author":"Fan","year":"2007","journal-title":"Zhongguo Ying Yong Sheng Li Xue Za Zhi"},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0730","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/FJC.0b013e3181d706ae","article-title":"Effects of arginine vasopressin on differentiation of cardiac fibroblasts into myofibroblasts","volume":"55","author":"Yan-Hong","year":"2010","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"21 Supplement","key":"10.1016\/j.cellsig.2015.07.021_bb0735","article-title":"Abstract 14201: vasopressin type 1a receptor deficiency prevents the onset of heart failure: possible link with myocardial fibrosis","volume":"122","author":"Takase","year":"2010","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.cellsig.2015.07.021_bb0740","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJM198604243141707","article-title":"The calcium messenger system (1)","volume":"314","author":"Rasmussen","year":"1986","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.cellsig.2015.07.021_bb0745","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJM198605013141807","article-title":"The calcium messenger system (2)","volume":"314","author":"Rasmussen","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2015.07.021_bb0750","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.bi.56.070187.002143","article-title":"Intracellular calcium homeostasis","volume":"56","author":"Carafoli","year":"1987","journal-title":"Annu. Rev. Biochem."},{"issue":"1 Pt 2","key":"10.1016\/j.cellsig.2015.07.021_bb0755","first-page":"R243","article-title":"Localization of the vasopressin V1a and V2 receptors within the renal cortical and medullary circulation","volume":"273","author":"Park","year":"1997","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.cellsig.2015.07.021_bb0760","doi-asserted-by":"crossref","first-page":"223S","DOI":"10.1111\/j.1469-445X.2000.tb00027.x","article-title":"Control of the renal medullary circulation by vasopressin V1 and V2 receptors in the rat","volume":"85","author":"Cowley","year":"2000","journal-title":"Exp. Physiol."},{"issue":"3","key":"10.1016\/j.cellsig.2015.07.021_bb0765","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0014-2999(96)00584-5","article-title":"Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney","volume":"314","author":"Barthelmebs","year":"1996","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.cellsig.2015.07.021_bb0770","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.bjp.0701102","article-title":"Mechanism of enhanced vasoconstrictor hormone action in vascular smooth muscle cells by cyclosporin a","volume":"121","author":"Lo Russo","year":"1997","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0775","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bjp.0703878","article-title":"Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin a treatment","volume":"132","author":"Cottet-Maire","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0780","doi-asserted-by":"crossref","first-page":"R191","DOI":"10.1152\/ajpregu.00047.2007","article-title":"Arginine vasopressin inhibits Kir6.1\/SUR2B channel and constricts the mesenteric artery via V1a receptor and protein kinase C","volume":"293","author":"Shi","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"2","key":"10.1016\/j.cellsig.2015.07.021_bb0785","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jss.2009.01.005","article-title":"Role of V1a receptor in AVP-induced restoration of vascular hyporeactivity and its relationship to MLCP-MLC20 phosphorylation pathway","volume":"161","author":"Yang","year":"2010","journal-title":"J. Surg. Res."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0790","doi-asserted-by":"crossref","first-page":"F997","DOI":"10.1152\/ajprenal.00399.2003","article-title":"Age-dependent regulation of vasopressin V1a receptors in preglomerular vessels from the spontaneously hypertensive rat","volume":"286","author":"Vagnes","year":"2004","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"6","key":"10.1016\/j.cellsig.2015.07.021_bb0795","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1046\/j.1523-1755.2002.00383.x","article-title":"Store-operated Ca2+ entry is exaggerated in fresh preglomerular vascular smooth muscle cells of SHR","volume":"61","author":"Fellner","year":"2002","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.cellsig.2015.07.021_bb0800","doi-asserted-by":"crossref","first-page":"F1023","DOI":"10.1152\/ajprenal.00175.2004","article-title":"Enhanced response to AVP in the interlobular artery from the spontaneously hypertensive rat","volume":"288","author":"Hansen","year":"2005","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"2 Pt 2","key":"10.1016\/j.cellsig.2015.07.021_bb0805","first-page":"F260","article-title":"Exaggerated Ca2+ signaling in preglomerular arteriolar smooth muscle cells of genetically hypertensive rats","volume":"276","author":"Iversen","year":"1999","journal-title":"Am. J. Physiol."},{"issue":"3","key":"10.1016\/j.cellsig.2015.07.021_bb0810","first-page":"349","article-title":"Vasopressin V1a, V1b and V2 receptors mRNA in the kidney and heart of the renin transgenic TGR(mRen2)27 and Sprague Dawley rats","volume":"53","author":"Gozdz","year":"2002","journal-title":"J. Physiol. Pharmacol."},{"issue":"6","key":"10.1016\/j.cellsig.2015.07.021_bb0815","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10157-013-0783-y","article-title":"The intercalated cells of the mouse kidney OMCD(is) are the target of the vasopressin V1a receptor axis for urinary acidification","volume":"17","author":"Yasuoka","year":"2013","journal-title":"Clin. Exp. Nephrol."},{"issue":"3","key":"10.1016\/j.cellsig.2015.07.021_bb0820","doi-asserted-by":"crossref","first-page":"F559","DOI":"10.1152\/ajprenal.00617.2009","article-title":"Vasopressin increases phosphorylation of Ser84 and Ser486 in Slc14a2 collecting duct urea transporters","volume":"299","author":"Hwang","year":"2010","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.cellsig.2015.07.021_bb0825","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/en.2008-0068","article-title":"Sustained elevated levels of circulating vasopressin selectively stimulate the proliferation of kidney tubular cells via the activation of V2 receptors","volume":"150","author":"Alonso","year":"2009","journal-title":"Endocrinology"},{"issue":"17","key":"10.1016\/j.cellsig.2015.07.021_bb0830","doi-asserted-by":"crossref","first-page":"E1028","DOI":"10.1073\/pnas.1112422109","article-title":"Engagement of beta-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1\/2 activation","volume":"109","author":"Oligny-Longpre","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.cellsig.2015.07.021_bb0835","doi-asserted-by":"crossref","first-page":"F177","DOI":"10.1152\/ajprenal.00431.2012","article-title":"Vasopressin inhibits apoptosis in renal collecting duct cells","volume":"304","author":"Miller","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1\u20133","key":"10.1016\/j.cellsig.2015.07.021_bb0840","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.regpep.2008.01.002","article-title":"Effect of vasopressin on type IV collagen production in human mesangial cells","volume":"147","author":"Tahara","year":"2008","journal-title":"Regul. Pept."},{"issue":"4","key":"10.1016\/j.cellsig.2015.07.021_bb0845","doi-asserted-by":"crossref","first-page":"F1170","DOI":"10.1152\/ajprenal.00119.2008","article-title":"Regulation of V2R transcription by hypertonicity and V1aR-V2R signal interaction","volume":"295","author":"Izumi","year":"2008","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"2","key":"10.1016\/j.cellsig.2015.07.021_bb0850","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacc.2015.04.071","article-title":"Intracoronary cytoprotective gene therapy: a study of VEGF-B167 in a Pre-clinical animal model of dilated cardiomyopathy","volume":"66","author":"Woitek","year":"2015","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656815002181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656815002181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T16:30:46Z","timestamp":1748536246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656815002181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":170,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0898656815002181"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2015.07.021","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arginine vasopressin receptor signaling and functional outcomes in heart failure","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2015.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}